Epilepsy trials in Czechia

Showing 26 to 50 of 63. Each trial links to its page on Pharma Observatory.

• A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures NCT01964560·Phase 3·Completed·UCB BIOSCIENCES, Inc.·Started 2014
• A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years NCT02033902·Observational·Completed·Eisai Inc.·Started 2014
• Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU NCT01999777·Phase 3·Completed·UCB Biopharma S.P.R.L.·Started 2013
• Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex NCT02098759·Not applicable·Unknown status·Sergiusz Jozwiak·Started 2013
• Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures NCT01921205·Phase 3·Completed·UCB Pharma·Started 2013
• Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older NCT01465997·Phase 3·Completed·UCB BIOSCIENCES GmbH·Started 2012
• A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures NCT01463306·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2012
• A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years NCT01389596·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2011
• Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy NCT01405508·Phase 3·Completed·UCB Pharma·Started 2011
• Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy NCT01364597·Phase 3·Completed·UCB Pharma SA·Started 2011
• Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy. NCT00422422·Phase 2·Completed·UCB Pharma·Started 2011
• Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy NCT01339559·Phase 3·Completed·UCB BIOSCIENCES, Inc.·Started 2011
• Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older NCT01243177·Phase 3·Completed·UCB BIOSCIENCES GmbH·Started 2011
• Once-A-Day Pregabalin For Partial Seizures NCT01262677·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2011
• Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures NCT01261325·Phase 3·Completed·UCB Pharma·Started 2010
• A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents NCT01161524·Phase 2·Completed·Eisai Inc.·Started 2010
• Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic NCT01091662·Phase 3·Completed·Sumitomo Pharma America, Inc.·Started 2010
• Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients NCT01422720·Phase 3·Completed·Bial - Portela C S.A.·Started 2010
• Eslicarbazepine Acetate Monotherapy Long Term Study NCT00910247·Phase 3·Completed·Sumitomo Pharma America, Inc.·Started 2009
• An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam NCT00761774·Phase 3·Completed·UCB Pharma·Started 2008
• Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures NCT00735397·Phase 3·Completed·Eisai Inc.·Started 2008
• A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures NCT00698581·Phase 3·Terminated·UCB Pharma·Started 2008
• Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures NCT00692003·Phase 3·Terminated·Eisai Limited·Started 2008
• Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy NCT00693017·Phase 3·Terminated·Eisai Limited·Started 2008
• Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures NCT00596466·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2008